Early intervention for schizophrenia: The risk-benefit ratio of antipsychotic treatment in the prodromal phase

American Journal of Psychiatry

Volumn 168, Issue 8, 2011, Pages 761-763

  Weiser, Mark ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT;

ANXIETY; COGNITIVE DEFECT; COMORBIDITY; DEPRESSION; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; EDITORIAL; HUMAN; MENTAL DISEASE; METABOLIC DISORDER; NEGATIVE SYNDROME; NORTH AMERICA; PATIENT REFERRAL; PERSONALITY DISORDER; POSITIVE SYNDROME; PRIORITY JOURNAL; PRODROMAL PHASE; PSYCHOLOGIC ASSESSMENT; PSYCHOSIS; PSYCHOSOCIAL CARE; RISK BENEFIT ANALYSIS; SCHIZOPHRENIA; SOCIAL INTERACTION; SUBSTANCE ABUSE; TREATMENT RESPONSE;

ANTIPSYCHOTIC AGENTS; DISEASE PROGRESSION; EARLY DIAGNOSIS; HUMANS; LONGITUDINAL STUDIES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SCHIZOTYPAL PERSONALITY DISORDER; TREATMENT OUTCOME;

EID: 80052453468     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2011.11050765     Document Type: Editorial

References (14)

1. Sullivan H.S.: The onset of schizophrenia. 1927 (classical article): Am J Psychiatry 1994; 151:134-139
2. Yung A.R., McGorry P.D., McFarlane C.A., Jackson H.J., Patton G.C., Rakkar A.: Monitoring and care of young people at incipient risk of psychosis. Schizophr Bull 1996; 22:283-303 (Pubitemid 26174575)
3. Yung A.R., Phillips L.J., Yuen H.P., Francey S.M., McFarlane C.A., Hallgren M., McGorry P.D.: Psychosis prediction: 12-month follow up of a high-risk (prodromal) group. Schizophr Res 2003; 60:21-32 (Pubitemid 36015785)
4. McGorry P.D., Yung A.R., Phillips L.J., Yuen H.P., Francey S., Cosgrave E.M., Germano D., Bravin J., McDonald T., Blair A., Adlard S., Jackson H.: Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch Gen Psychiatry 2002; 59:921-928
5. McGlashan T.H., Zipursky R.B., Perkins D., Addington J., Miller T., Woods S.W., Hawkins K.A., Hoffman R.E., Preda A., Epstein I., Addington D., Lindborg S., Trzaskoma Q., Tohen M., Breier A.: Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry 2006; 163:790-799 (Pubitemid 44464525)
6. Cadenhead K.S., Addington J., Cannon T., Cornblatt B., McGlashan T., Perkins D., Seidman L., Tsuang M., Walker E., Woods S., Heinssen R.: Treatment history in the psychosis prodrome: Characteristics of the North American Prodrome Longitudinal Study cohort. Early Interv Psychiatry 2010; 4:220-226
7. Yung A.R., Yuen H.P., Berger G., Francey S., Hung T.C., Nelson B., Phillips L., McGorry P.: Declining transition rate in ultra high risk (prodromal) services: Dilution or reduction of risk? Schizophr Bull 2007; 33:673-681 (Pubitemid 47343718)
8. Ruhrmann S., Schultze-Lutter F., Klosterkötter J.: Probably at-risk, but certainly ill: Advocating the introduction of a psychosis spectrum disorder in DSM-V. Schizophr Res 2010; 120:23-37
9. Cannon T.D., Cornblatt B., McGorry P.: The empirical status of the ultra high-risk (prodromal) research paradigm. Schizophr Bull 2007; 33:661-664 (Pubitemid 47343732)
10. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Keefe R.S., Davis S.M., Davis C.E., Lebowitz B.D., Severe J., Hsiao J.K.; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353:1209-1223
11. Addington J., Cornblatt B.A., Cadenhead K.S., Cannon T.D., McGlashan T.H., Perkins D.O., Seidman L.J., Tsuang M.T., Walker E.F., Woods S.W., Heinssen R.: At clinical high risk for psychosis: Outcome for nonconverters. Am J Psychiatry 2011; 168:800-805
12. Rabinowitz J.A., Reichenberg A., Weiser M., Mark M., Kaplan Z., Davidson M.: Cognitive and behavioural functioning in men with schizophrenia both before and shortly after first admission to hospital: Cross-sectional analysis. Br J Psychiatry 2000; 177:26-32 (Pubitemid 30450660)
13. Reichenberg A., Weiser M., Rapp M.A., Rabinowitz J., Caspi A., Schmeidler J., Knobler H.Y., Lubin G., Nahon D., Harvey P.D., Davidson M.: Elaboration on premorbid intellectual performance in schizophrenia: Premorbid intellectual decline and risk for schizophrenia. Arch Gen Psychiatry 2005; 62:1297-1304 (Pubitemid 41746607)
14. Carrión R.E., Goldberg T.E., McLaughlin D., Auther A.M., Correll C.U., Cornblatt B.A.: Impact of neurocognition on social and role functioning in individuals at clinical high risk for psychosis. Am J Psychiatry 2011; 168:806-813